Literature DB >> 24280573

MUC2 expression and prevalence of high-grade dysplasia and invasive carcinoma in mixed-type intraductal papillary mucinous neoplasm of the pancreas.

Atsuhiro Masuda1, Yoshifumi Arisaka, Shigeo Hara, Ippei Matsumoto, Mamoru Takenaka, Arata Sakai, Hideyuki Shiomi, Nobuyuki Matsuki, Maki Sugimoto, Tsuyoshi Fujita, Takanobu Hayakumo, Yonson Ku, Shuji Ogino, Takeshi Azuma, Hiromu Kutsumi.   

Abstract

BACKGROUND/
OBJECTIVES: Morphological types and mucin protein expressions classify intraductal papillary mucinous neoplasms (IPMNs). Main duct (MD)-IPMN mostly consists of intestinal type (I-type), which expresses MUC2. Branch duct (BD)-IPMN mostly consists of gastric type (G-type), which does not express MUC2. However, the definition of mixed-type IPMN has yet to be clarified and it contains various histological types. The aim of this study was to investigate the relationship between MUC2 expression and the presence of high-grade dysplasia (HGD) and invasive carcinoma, especially in mixed-type IPMN.
METHODS: This retrospective study included 101 consecutive patients with surgically resected IPMNs between April 2001 and October 2012. All patients were morphologically classified into four distinct types (I-type, G-type, PB-type: pancreatobilliary, O-type: oncocytic) and immunohistochemical reactivity of various anti-mucin antibodies were investigated.
RESULTS: According to the classification of the 2012 international guidelines, the numbers (and histomorphological types: I/G/PB/O) of MD, mixed-type, and BD-IPMNs were 16 (12/4/0/0), 45 (16/28/1/0), and 40 (0/38/1/1). Prevalence of MUC2 expression in MD, mixed-type, and BD-IPMNs were 75% (12/16), 36% (16/45), and 0% (0/40). In mixed-type IPMN, the prevalence of HGD and/or invasive carcinoma in MUC2-positive IPMN was significantly higher than that of MUC2-negative IPMN (HGD + invasive carcinoma: 88% vs. 38%, p = 0.0017; invasive carcinoma: 50% vs. 21%, p = 0.042). Multivariate analysis showed that MUC2 expression is an independent predictive factor of HGD and invasive carcinoma in mixed IPMN (odds ratio 14.6, 95% CI 2.5-87.4, p = 0.003).
CONCLUSIONS: In mixed-type IPMN, MUC2 expression clearly identified HGD and invasive carcinoma and may provide most appropriate surgical indication.
Copyright © 2013 IAP and EPC. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  BD-IPMN; CT; ERCP; EUS; EUS-FNA; HGD; High-grade dysplasia; IPMN; Invasive carcinoma; LGD; MCN; MD-IPMN; MPD; MRCP; MRI; MUC2 expression; Mixed-type IPMN; branch duct intraductal papillary mucinous neoplasm; computed tomography; endoscopic retrograde cholangiopancreatography; endoscopic ultrasonography; endoscopic ultrasound-guided fine needle aspiration; high-grade dysplasia; intraductal papillary mucinous neoplasm; low-grade dysplasia; magnetic resonance cholangiopancreatography; magnetic resonance imaging; main duct intraductal papillary mucinous neoplasm; main pancreatic duct; mucinous cystic neoplasm

Mesh:

Substances:

Year:  2013        PMID: 24280573     DOI: 10.1016/j.pan.2013.08.007

Source DB:  PubMed          Journal:  Pancreatology        ISSN: 1424-3903            Impact factor:   3.996


  6 in total

1.  Pathologic Evaluation and Reporting of Intraductal Papillary Mucinous Neoplasms of the Pancreas and Other Tumoral Intraepithelial Neoplasms of Pancreatobiliary Tract: Recommendations of Verona Consensus Meeting.

Authors:  Volkan Adsay; Mari Mino-Kenudson; Toru Furukawa; Olca Basturk; Giuseppe Zamboni; Giovanni Marchegiani; Claudio Bassi; Roberto Salvia; Giuseppe Malleo; Salvatore Paiella; Christopher L Wolfgang; Hanno Matthaei; G Johan Offerhaus; Mustapha Adham; Marco J Bruno; Michelle D Reid; Alyssa Krasinskas; Günter Klöppel; Nobuyuki Ohike; Takuma Tajiri; Kee-Taek Jang; Juan Carlos Roa; Peter Allen; Carlos Fernández-del Castillo; Jin-Young Jang; David S Klimstra; Ralph H Hruban
Journal:  Ann Surg       Date:  2016-01       Impact factor: 12.969

2.  Mucins in pancreatic cancer: biological role, implications in carcinogenesis and applications in diagnosis and therapy.

Authors:  Hyerim Suh; Krishna Pillai; David Lawson Morris
Journal:  Am J Cancer Res       Date:  2017-06-01       Impact factor: 6.166

Review 3.  Elevating pancreatic cystic lesion stratification: Current and future pancreatic cancer biomarker(s).

Authors:  Joseph Carmicheal; Asish Patel; Vipin Dalal; Pranita Atri; Amaninder S Dhaliwal; Uwe A Wittel; Mokenge P Malafa; Geoffrey Talmon; Benjamin J Swanson; Shailender Singh; Maneesh Jain; Sukhwinder Kaur; Surinder K Batra
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2019-10-30       Impact factor: 10.680

4.  Mucin Expression in Mucinous Pancreatic Cysts: Can String Sign Test Predict Mucin Types? A Single Center Pilot Study.

Authors:  İbrahim Hakkı Köker; Nurcan Ünver; Fatma Ümit Malya; Ömer Uysal; Elmas Biberci Keskin; Hakan Şentürk
Journal:  Turk J Gastroenterol       Date:  2021-02       Impact factor: 1.852

5.  Intraductal papillary-mucinous carcinoma with portal vein tumor thrombus and multifocal liver metastasis: An autopsy case.

Authors:  Naohiro Matsushita; Akitoshi Douhara; Hirotsugu Ueno; Shohei Asada; Koji Murata; Koji Yanase; Masahiro Tsutsumi
Journal:  Mol Clin Oncol       Date:  2021-03-13

Review 6.  Management of Incidental Pancreatic Cystic Lesions.

Authors:  Christian Jenssen; Stefan Kahl
Journal:  Viszeralmedizin       Date:  2015-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.